Back to Search
Start Over
Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon [beta]
- Source :
- Proceedings of the National Academy of Sciences of the United States. June 8, 2004, Vol. 101 Issue 23, p8705, 4 p.
- Publication Year :
- 2004
-
Abstract
- Identifying effective treatment combinations for MS patients failing standard therapy is an important goal. We report the results of a phase II open label baseline-to-treatment trial of a humanized monoclonal antibody against CD25 (daclizumab) in 10 multiple sclerosis patients with incomplete response to IFN-[beta] therapy and high brain inflammatory and clinical disease activity. Daclizumab was very well tolerated and led to a 78% reduction in new contrast-enhancing lesions and to a significant improvement in several clinical outcome measures.
Details
- Language :
- English
- ISSN :
- 00278424
- Volume :
- 101
- Issue :
- 23
- Database :
- Gale General OneFile
- Journal :
- Proceedings of the National Academy of Sciences of the United States
- Publication Type :
- Academic Journal
- Accession number :
- edsgcl.119782225